Literature DB >> 19967367

Determinants of local progression after computed tomography-guided percutaneous radiofrequency ablation for unresectable lung tumors: 9-year experience in a single institution.

Tomohisa Okuma1, Toshiyuki Matsuoka, Akira Yamamoto, Yoshimasa Oyama, Shinichi Hamamoto, Masami Toyoshima, Kenji Nakamura, Yukio Miki.   

Abstract

The purpose of this study was to retrospectively determine the local control rate and contributing factors to local progression after computed tomography (CT)-guided radiofrequency ablation (RFA) for unresectable lung tumor. This study included 138 lung tumors in 72 patients (56 men and 16 women; age 70.0 +/- 11.6 years (range 31-94); mean tumor size 2.1 +/- 1.2 cm [range 0.2-9]) who underwent lung RFA between June 2000 and May 2009. Mean follow-up periods for patients and tumors were 14 and 12 months, respectively. The local progression-free rate and survival rate were calculated to determine the contributing factors to local progression. During follow-up, 44 of 138 (32%) lung tumors showed local progression. The 1-, 2-, 3-, and 5-year overall local control rates were 61, 57, 57, and 38%, respectively. The risk factors for local progression were age (>or=70 years), tumor size (>or=2 cm), sex (male), and no achievement of roll-off during RFA (P < 0.05). Multivariate analysis identified tumor size >or=2 cm as the only independent factor for local progression (P = 0.003). For tumors <2 cm, 17 of 68 (25%) showed local progression, and the 1-, 2-, and 3-year overall local control rates were 77, 73, and 73%, respectively. Multivariate analysis identified that age >or=70 years was an independent determinant of local progression for tumors <2 cm in diameter (P = 0.011). The present study showed that 32% of lung tumors developed local progression after CT-guided RFA. The significant risk factor for local progression after RFA for lung tumors was tumor size >or=2 cm.

Entities:  

Mesh:

Year:  2009        PMID: 19967367     DOI: 10.1007/s00270-009-9770-9

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  19 in total

1.  Evaluation of carcinoembryonic antigen (CEA) density as a prognostic factor for percutaneous ablation of pulmonary colorectal metastases.

Authors:  Ya Ruth Huo; Derek Glenn; Winston Liauw; Mark Power; Jing Zhao; David L Morris
Journal:  Eur Radiol       Date:  2016-05-10       Impact factor: 5.315

Review 2.  The role of percutaneous image-guided ablation for lung tumors.

Authors:  Elena N Petre; Stephen B Solomon; Constantinos T Sofocleous
Journal:  Radiol Med       Date:  2014-07-01       Impact factor: 3.469

Review 3.  Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances.

Authors:  S L Smith; P E Jennings
Journal:  Br J Radiol       Date:  2014-12-03       Impact factor: 3.039

Review 4.  Lung Ablation: Indications and Techniques.

Authors:  Bashir Akhavan Tafti; Scott Genshaft; Robert Suh; Fereidoun Abtin
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

5.  A synthetic tryptophan metabolite reduces hemorrhagic area and inflammation after pulmonary radiofrequency ablation in rabbit nonneoplastic lungs.

Authors:  Hiroshi Nakada; Atsushi Yamashita; Masaomi Kuroki; Eiji Furukoji; Noriko Uchino; Taketoshi Asanuma; Yujiro Asada; Shozo Tamura
Journal:  Jpn J Radiol       Date:  2014-01-22       Impact factor: 2.374

Review 6.  The Importance of Biopsy in the Era of Molecular Medicine.

Authors:  Etay Ziv; Jeremy C Durack; Stephen B Solomon
Journal:  Cancer J       Date:  2016 Nov/Dec       Impact factor: 3.360

7.  Understanding the possibility of image-guided thermal ablation for pulmonary malignancies.

Authors:  Hideki Ujiie; Kazuhiro Yasufuku
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 8.  Lung cancer ablation: what is the evidence?

Authors:  Thierry de Baere; Geoffroy Farouil; Frederic Deschamps
Journal:  Semin Intervent Radiol       Date:  2013-06       Impact factor: 1.513

9.  Non-surgical management of stage I lung cancer.

Authors:  Elizabeth M Gore
Journal:  F1000 Med Rep       Date:  2010-03-25

10.  Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.

Authors:  Etay Ziv; Joseph P Erinjeri; Hooman Yarmohammadi; F Edward Boas; Elena N Petre; Song Gao; Waleed Shady; Constantinos T Sofocleous; David R Jones; Charles M Rudin; Stephen B Solomon
Journal:  Radiology       Date:  2016-07-19       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.